# Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

> **NCT00601718** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Washington** · enrollment: 29 (actual)

## Conditions studied

- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Anaplastic Large Cell Lymphoma
- Angioimmunoblastic T-cell Lymphoma
- Contiguous Stage II Mantle Cell Lymphoma
- Cutaneous B-cell Non-Hodgkin Lymphoma
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Nodal Marginal Zone B-cell Lymphoma
- Noncontiguous Stage II Mantle Cell Lymphoma
- Recurrent Adult Burkitt Lymphoma
- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Adult Diffuse Mixed Cell Lymphoma
- Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
- Recurrent Adult Grade III Lymphomatoid Granulomatosis
- Recurrent Adult Hodgkin Lymphoma
- Recurrent Adult Immunoblastic Large Cell Lymphoma
- Recurrent Adult Lymphoblastic Lymphoma
- Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
- Recurrent Mycosis Fungoides/Sezary Syndrome
- Recurrent Small Lymphocytic Lymphoma
- Splenic Marginal Zone Lymphoma
- Stage I Cutaneous T-cell Non-Hodgkin Lymphoma
- Stage I Mantle Cell Lymphoma
- Stage I Mycosis Fungoides/Sezary Syndrome
- Stage II Cutaneous T-cell Non-Hodgkin Lymphoma
- Stage II Mycosis Fungoides/Sezary Syndrome
- Stage III Cutaneous T-cell Non-Hodgkin Lymphoma
- Stage III Mantle Cell Lymphoma
- Stage III Mycosis Fungoides/Sezary Syndrome
- Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma
- Stage IV Mantle Cell Lymphoma
- Stage IV Mycosis Fungoides/Sezary Syndrome
- Waldenström Macroglobulinemia

## Interventions

- **DRUG:** vorinostat
- **BIOLOGICAL:** rituximab
- **DRUG:** ifosfamide
- **DRUG:** carboplatin
- **DRUG:** etoposide
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis
- **GENETIC:** gene expression analysis

## Key facts

- **NCT ID:** NCT00601718
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2010-06
- **Final completion:** —
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2017-05-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00601718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00601718, "Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00601718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*